Imunon, Inc. Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss
Imunon, Inc. (IMNN) had Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss of $97.10 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Balance Sheet › Assets
us-gaap:DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss · last filed 2024-03-28
- 2023-09-30: Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss $97.10K.
- 2023-06-30: Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss $80.49K.
- 2023-03-31: Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss $116.36K.
- 2022-12-31: Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss $128.93K.
| Period end | Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss |
|---|---|
| 2023-09-30 | $97.10K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $80.49K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $116.36K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $128.93K 10-K · filed 2024-03-28 |
| 2022-09-30 | $30.50K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $29.73K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $15.65K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $108.84K 10-K · filed 2023-03-30 |
| 2021-09-30 | $38.40K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $105.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |